These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11817317)

  • 21. The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients.
    Johnson DW; Clark C; Isbel NM; Hawley CM; Beller E; Cass A; de Zoysa J; McTaggart S; Playford G; Rosser B; Thompson C; Snelling P;
    Perit Dial Int; 2009; 29(3):303-9. PubMed ID: 19458303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Pulse" nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis.
    Mylotte JM; Kahler L; Jackson E
    Infect Control Hosp Epidemiol; 1999 Nov; 20(11):741-5. PubMed ID: 10580624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prophylaxis and management of catheter-associated infections in peritoneal dialysis patients: recent studies and guidelines].
    Kopriva-Altfahrt G; Moser E; Prokschi A; Kraus B; Kovarik J
    Wien Klin Wochenschr; 2005; 117 Suppl 6():73-82. PubMed ID: 16437337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.
    Bernardini J; Bender F; Florio T; Sloand J; Palmmontalbano L; Fried L; Piraino B
    J Am Soc Nephrol; 2005 Feb; 16(2):539-45. PubMed ID: 15625071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study.
    Pommer W; Brauner M; Westphale HJ; Brunkhorst R; Krämer R; Bundschu D; Höffken B; Steinhauer HB; Schümann E; Lüttgen FM; Schillinger-Pokorny E; Schaefer F; Wende R; Offner G; Näther S; Osten B; Zimmering M; Ehrich JH; Kehn M; Mansmann U; Grosse-Siestrup C
    Am J Kidney Dis; 1998 Nov; 32(5):752-60. PubMed ID: 9820444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients.
    Vas SI; Conly J; Bargman JM; Oreopoulos DG
    Perit Dial Int; 1999; 19(4):313-4. PubMed ID: 10507810
    [No Abstract]   [Full Text] [Related]  

  • 27. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.
    Luzar MA; Coles GA; Faller B; Slingeneyer A; Dah GD; Briat C; Wone C; Knefati Y; Kessler M; Peluso F
    N Engl J Med; 1990 Feb; 322(8):505-9. PubMed ID: 2300122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
    Cavdar C; Saglam F; Sifil A; Celik A; Atay T; Gungor O; Ozder A; Gulay Z; Camsari T
    Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients.
    Htay H; Johnson DW; Wu SY; Oei EL; Foo MWY; Choo JCJ
    Perit Dial Int; 2017; 37(3):266-272. PubMed ID: 28183858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of nasal carriage of Staphylococcus aureus--is it cost-effective?
    Davey P
    J Hosp Infect; 1998 Sep; 40 Suppl B():S31-7. PubMed ID: 9777531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results.
    Pérez-Fontán M; García-Falcón T; Rosales M; Rodríguez-Carmona A; Adeva M; Rodríguez-Lozano I; Moncalián J
    Am J Kidney Dis; 1993 Nov; 22(5):708-12. PubMed ID: 8238017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
    Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
    Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Staphylococcus aureus nasal carriage: role in continuous ambulatory peritoneal dialysis-associated infections.
    Herwaldt LA
    Perit Dial Int; 1993; 13 Suppl 2():S301-5. PubMed ID: 8399593
    [No Abstract]   [Full Text] [Related]  

  • 34. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis.
    Tacconelli E; Carmeli Y; Aizer A; Ferreira G; Foreman MG; D'Agata EM
    Clin Infect Dis; 2003 Dec; 37(12):1629-38. PubMed ID: 14689344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site.
    Wong SS; Chu KH; Cheuk A; Tsang WK; Fung SK; Chan HW; Tong MK
    Perit Dial Int; 2003 Dec; 23 Suppl 2():S153-8. PubMed ID: 17986538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis?
    Conly JM; Vas S
    Perit Dial Int; 2002; 22(6):649-52. PubMed ID: 12556065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.
    Hanslik TM; Newman L; Tessman M; Morrissey AB; Friedlander MA
    Adv Perit Dial; 1994; 10():158-62. PubMed ID: 7999817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
    Sesso R; Parisio K; Dalboni A; Rabelo T; Barbosa D; Cendoroglo M; Pignatari A; Draibe S; Ajzen H
    Clin Nephrol; 1994 Jun; 41(6):370-6. PubMed ID: 8076441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis.
    Bloom BS; Fendrick AM; Chernew ME; Patel P
    Am J Kidney Dis; 1996 May; 27(5):687-94. PubMed ID: 8629629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population.
    Mahajan S; Tiwari SC; Kalra V; Bhowmik DM; Agarwal SK; Dash SC; Kumar P
    Perit Dial Int; 2005; 25(5):473-7. PubMed ID: 16178481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.